In short: Giroux: in his seven-name SMID-biotech takeout basket (50–100% premium potential as large pharma fills its $400–500B patent hole); Phase 2/3 assets against serious conditions with $2–10B revenue potential.
Nothing matches this filter.
Verbatim excerpts from the public transcripts (auto-pulled at each mention's timestamp, lightly cleaned). Timestamps link into the video; "source page" opens that commentator's full analysis at this row. Click a mention's header line to expand it (one open at a time). For personal study — not investment advice.